News Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:35:16 2024-05-31 am EDT			5-day change	1st Jan Change
3.305 ^EUR	+3.93%		+0.46%	-19.29%

May. 24	Inventiva: UBS Group sells its stake	CF
May. 22	Inventiva: share price falls, cash flow concerns	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inventiva : 14. Brochure General Assembly 06 20 2024	May. 30	PU
Inventiva : 7. Special Report of the Board of Directors on Bonus Share Issues – AGA 2023 – 25 03 2024	May. 30	PU
Inventiva : 1. Agenda of Ordinary and Extraordinary General Meeting – 06 20 2024	May. 30	PU
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	May. 30	GL
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents	May. 30	AQ
Inventiva : Franchissement de seuil	May. 27	PU
Inventiva: UBS Group sells its stake	May. 24	CF
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024	May. 22	GL
Inventiva: share price falls, cash flow concerns	May. 22	CF
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update	May. 21	GL
Inventiva: DMC recommends continuation of study	May. 17	CF
Inventiva, Inc. Announces Amendments to the Pipeline Programs and Clinical Trials	May. 16	CI
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH	May. 16	GL
Inventiva : Notice of meeting to the Ordinary and Extraordinary General Meeting dated June 20, 2024 - Form 6-K	May. 13	PU
Inventiva: additional Phase 2 results in NASH	May. 13	CF
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor	May. 13	GL
Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor	May. 13	CI
Inventiva : Présentation corporate avril 2024	Apr. 30	PU
Inventiva: UBS Group falls below 5% threshold	Apr. 22	CF
Transcript : Inventiva S.A. - Special Call	Apr. 17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Inventiva

Equities

IVA

FR0013233012

Summary

Filters